Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Exchange Rate Effect (2020 - 2025)

Historic Exchange Rate Effect for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $22000.0.

  • Apellis Pharmaceuticals' Exchange Rate Effect fell 8728.32% to $22000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $101000.0, marking a year-over-year decrease of 8865.17%. This contributed to the annual value of -$659000.0 for FY2024, which is 58814.81% down from last year.
  • Apellis Pharmaceuticals' Exchange Rate Effect amounted to $22000.0 in Q3 2025, which was down 8728.32% from $685000.0 recorded in Q2 2025.
  • Apellis Pharmaceuticals' Exchange Rate Effect's 5-year high stood at $685000.0 during Q2 2025, with a 5-year trough of -$1.6 million in Q1 2021.
  • For the 5-year period, Apellis Pharmaceuticals' Exchange Rate Effect averaged around -$103263.2, with its median value being $8000.0 (2021).
  • Its Exchange Rate Effect has fluctuated over the past 5 years, first crashed by 95986.84% in 2021, then soared by 223750.0% in 2022.
  • Quarter analysis of 5 years shows Apellis Pharmaceuticals' Exchange Rate Effect stood at $8000.0 in 2021, then surged by 2237.5% to $187000.0 in 2022, then soared by 212.3% to $584000.0 in 2023, then crashed by 265.24% to -$965000.0 in 2024, then soared by 102.28% to $22000.0 in 2025.
  • Its last three reported values are $22000.0 in Q3 2025, $685000.0 for Q2 2025, and $359000.0 during Q1 2025.